{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-100211","form_type":"8-K/A","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.457840+00:00","generated_at":"2026-05-31T07:50:27.208275+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Akari Therapeutics discloses CEO separation terms: $450K payment, RSU vesting/forfeiture","bullets":["Rachelle Jacques stepped down as President and CEO effective May 1, 2024.","Separation agreement on Aug 19, 2024 provides $450K lump sum payment contingent on merger close or by Dec 2, 2024.","Vesting of RSUs representing 276M ordinary shares; forfeiture of RSUs representing 482.25M ordinary shares.","Payment condition tied to anticipated merger with Peak Bio, Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-100211","json":"https://secwatch.observer/filing/0000950170-24-100211.json","markdown":"https://secwatch.observer/filing/0000950170-24-100211.md","text":"https://secwatch.observer/filing/0000950170-24-100211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024100211/0000950170-24-100211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024100211/aktx-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:50:27.208275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5b07cf1fa","claim":"Rachelle Jacques departed as President and Chief Executive Officer at Akari Therapeutics Plc.","evidence_excerpt":"Rachelle Jacques stepped down as the President and Chief Executive Officer of the Company, effective May 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024100211/0000950170-24-100211-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}